GLP2TZ is a synthetic dual-agonist peptide that targets both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) receptors, and it has been extensively studied in human clinical research. In trials with people who have type 2 diabetes, it has been shown to significantly reduce HbA1c (blood sugar) levels. Human studies also report substantial, dose-dependent weight loss in individuals with obesity or overweight, with a favorable safety profile. Research has demonstrated that GLP2TZ may improve metabolic parameters, such as insulin sensitivity and waist circumference, while also modulating cardiometabolic biomarkers. In a recent phase 3 trial, it reduced heart-failure–related outcomes and improved physical function and symptoms in people with obesity and heart failure with preserved ejection fraction. Across clinical research, GLP2TZ has become a valuable tool to study metabolic regulation, hormonal signaling, and dual-incretin receptor activity. Research Use Only. Not For Human or Veterinary Use.